Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation


Shanghai, China – Recently, Shanghai MicroPort Medical Group Co., Ltd. ("MicroPort®") was awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation, the only medical device company among the ten selected enterprises. To facilitate the implantation of Shanghai government's innovation-driven strategies to build a technological innovation center in the city and enhance its innovation ability, creativity and competitiveness, Science and Technology Commission of Shanghai Municipality and other city governmental authorities launched the "Innovative Enterprise Cultivation Program" this year to select enterprise with outstanding innovation abilities.
It is reported that the pilot enterprises of this program are all leaders of high-tech or strategic emerging industries with annual revenue exceeding one billion yuan, and at the same time, these enterprises should invest more than 5% of its revenue into research and development ("R&D") and have established scientific innovation system. The pilot program lasts for three years from 1 January 2017 to 31 December 2019, during which the Science and Technology Commission of Shanghai Municipality will offer favorable policies and resources based on the needs of the pilot enterprises to help strengthen their innovation abilities and promote a demonstration effect in terms of innovation, strategic management, globalization, and entrepreneurship for other Shanghai-based companies.
As a leading high-end medical device company in China, MicroPort®'s sustainable ability to innovate drives the company's future. In recent years, MicroPort® invests around 15% of its revenue into R&D annually. It has over 1,800 issued patents and more than 200 products approved for use worldwide, covering 10 major medical disciplines including interventional cardiology, orthopedics, interventional radiology, electrophysiology, diabetes and endocrine management, surgical management, and others. MicroPort® holds a leading position in China's drug eluting stent field since the launch of its drug-eluting stent in 2004, which is China's first domestically made drug-eluting stent. In particular, the launch of the world's first target-eluting stent in 2014 represented major leaps forward for MicroPort®, transforming its drug-eluting-stent offering from a market follower to a leader in this segment. In the future, MicroPort® will continue to strive for innovation, improve product offering and company governance, and focus on creating a sound environment for innovation and an efficient mechanism to cultivate innovative talents, and act as a role model to promote the development of China's high-end medical device industry.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Selected as "2017 China Innovative Medical Device Company"
[Next]:MicroPort® Orthopedics Attends 12th COA